aiqbench takeAI + Quantum

Iambic's IPO highlights a growing trend where biotech firms rely on AI-driven automated chemistry to accelerate drug discovery, with NVIDIA providing critical infrastructure support for these computational workflows. The successful pricing and entry of IAM1363 into clinical trials demonstrate the tangible commercial viability of integrating large-scale AI models into pharmaceutical R&D pipelines. This event underscores the deepening intersection between generative AI capabilities and high-value healthcare applications rather than representing a general tech market move.

Source covering36Kr

What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

NVIDIA-backed AI drugmaker Iambic prices IPO at $16, raising $150 million

36KrOctober 14, 20261 min read

On October 14 local time, AI pharmaceutical company Iambic Therapeutics announced its initial public offering (IPO) pricing of $16 per share, issuing 9.375 million shares and raising an expected $150 million, with underwriters granted a 30-day option to purchase up to an additional 1.40625 million shares. The company's stock is expected to begin trading on the Nasdaq Global Select Market on October 15 under the ticker symbol 'IAM', with the offering scheduled for completion on October 16. JPMorgan, Jefferies, Bank of America Securities, and Citigroup serve as joint bookrunners. Iambic leverages artificial intelligence and automated chemistry and biology techniques to advance drug discovery, with its candidate drug IAM1363 already in clinical development. NVIDIA previously participated in supporting the company's financing. (Jiemian)

Read the full article at 36Kr

Read at 36Kr ↗Ask about this article